This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...

Hello Health Rounds Readers! Today we feature a sneak peek at a trio of studies to be presented at the American Heart ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Butterfly Network, Inc. ("Butterfly") , a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced that ...

The Galien Foundation was established to foster and reward outstanding achievements in improving the global human condition ...

Belzutifan has a “generally manageable” safety profile in patients with RCC, with a relatively low rate of treatment discontinuation.

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...